184 related articles for article (PubMed ID: 36568275)
1. Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice.
Fröhlich D; Kalotay E; von Jonquieres G; Bongers A; Lee B; Suchowerska AK; Housley GD; Klugmann M
Front Mol Neurosci; 2022; 15():1061257. PubMed ID: 36568275
[TBL] [Abstract][Full Text] [Related]
2. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
[TBL] [Abstract][Full Text] [Related]
3. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
4. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
[TBL] [Abstract][Full Text] [Related]
5. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
6. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
7. Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation.
Corti M; Byrne BJ; Gessler DJ; Thompson G; Norman S; Lammers J; Coleman KE; Liberati C; Elder ME; Escolar ML; Tuna IS; Mesaros C; Kleiner GI; Barbouth DS; Gray-Edwards HL; Clement N; Cleaver BD; Gao G
Mol Ther Methods Clin Dev; 2023 Sep; 30():303-314. PubMed ID: 37601414
[TBL] [Abstract][Full Text] [Related]
8. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
9. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
[TBL] [Abstract][Full Text] [Related]
10. Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice.
Hull VL; Wang Y; Burns T; Sternbach S; Gong S; McDonough J; Guo F; Borodinsky LN; Pleasure D
Glia; 2023 Dec; 71(12):2832-2849. PubMed ID: 37610133
[TBL] [Abstract][Full Text] [Related]
11. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model.
Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D
Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859
[TBL] [Abstract][Full Text] [Related]
12. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy.
Hull VL; Wang Y; McDonough J; Zhu M; Burns T; Al Ramel N; Dehghani A; Guo F; Pleasure D
Ann Clin Transl Neurol; 2024 Apr; 11(4):1059-1062. PubMed ID: 38282243
[TBL] [Abstract][Full Text] [Related]
13. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up after gene therapy for canavan disease.
Leone P; Shera D; McPhee SW; Francis JS; Kolodny EH; Bilaniuk LT; Wang DJ; Assadi M; Goldfarb O; Goldman HW; Freese A; Young D; During MJ; Samulski RJ; Janson CG
Sci Transl Med; 2012 Dec; 4(165):165ra163. PubMed ID: 23253610
[TBL] [Abstract][Full Text] [Related]
15. Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs.
Feng L; Chao J; Tian E; Li L; Ye P; Zhang M; Chen X; Cui Q; Sun G; Zhou T; Felix G; Qin Y; Li W; Meza ED; Klein J; Ghoda L; Hu W; Luo Y; Dang W; Hsu D; Gold J; Goldman SA; Matalon R; Shi Y
Adv Sci (Weinh); 2020 Dec; 7(23):2002155. PubMed ID: 33304759
[TBL] [Abstract][Full Text] [Related]
16. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
[TBL] [Abstract][Full Text] [Related]
17. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
Becker I; Wang-Eckhardt L; Eckhardt M
J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease.
Grønbæk-Thygesen M; Hartmann-Petersen R
Cell Biosci; 2024 Apr; 14(1):45. PubMed ID: 38582917
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology and Treatment of Canavan Disease.
Pleasure D; Guo F; Chechneva O; Bannerman P; McDonough J; Burns T; Wang Y; Hull V
Neurochem Res; 2020 Mar; 45(3):561-565. PubMed ID: 30535831
[No Abstract] [Full Text] [Related]
20. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]